Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib + Dihydroartemisinin in Advanced NSCLC
NCT03402464Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2018
- Primary completion
- Jun 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dihydroartemisinin in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
dihydroartemisinin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03402464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402464.